067 Metformin in insulin resistant LV dysfunction, a double-blind, placebo controlled trial (Tayside trial)

Wong, Aaron; Symon, Ruth; ADZjali, M; Ang, D. S. C.; Choy, Anna Maria; Petrie, John R.; Struthers, Allan D.; Lang, Chim C.

doi:10.1136/hrt.2010.195966.15

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, metformin is recommended as first-line therapy for overweight patients with HF and T2DM who do not have renal dysfunction (GFR > 30 ml/min) [52]. A recent small trial (n = 62) found that treatment with metformin improved IR, glucose homeostasis, NYHA class and sub-maximal exercise parameters in non-diabetic patients with HF and IR, compared to placebo [62].…”

Section: Management Of Glucose In Patients With Diabetes and Heart Famentioning

confidence: 99%

Glucose and Insulin Abnormalities in Patients with Heart Failure

Deaton

Mamas

Rutter

et al. 2010

European Journal of Cardiovascular Nursing

View full text Add to dashboard Cite

The proportion of patients with heart failure (HF) who have diabetes is increasing. Patients with HF not known to be diabetic are at high risk of developing insulin resistance and impaired glucose tolerance, although the true prevalence and incidence are unknown. Despite the frequent co-occurrence of these conditions we have little evidence to direct prevention, screening and management of these patients, although earlier identification is advocated. This clinical update will define abnormal glucose levels and insulin resistance, review the pathophysiology, prevalence and incidence of glucose and insulin abnormalities in patients with HF, discuss prognostic implications, and make recommendations for clinical practice.

show abstract

Section: Management Of Glucose In Patients With Diabetes and Heart Famentioning

confidence: 99%

Glucose and Insulin Abnormalities in Patients with Heart Failure

Deaton

Mamas

Rutter

et al. 2010

European Journal of Cardiovascular Nursing

View full text Add to dashboard Cite

show abstract

Cardiovascular Effects of Metformin

Kurmanbekova

Noruizbaeva

2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Type 2 diabetes mellitus is one of the most important independent risk factors for the development, progression and mortality from cardiovascular diseases (CVD). The world communities are faced with the question of developing the optimal management tactics for such comorbidity patients. Thus, the prescribed drug should not only have an adequate hypoglycemic effect, but also have a number of cardioprotective properties, be safe in patients with CVD, and possibly even improve the prognosis and reduce mortality rates. This review is devoted to a representative of the biguanide class - metformin, which is one of the earliest and most effective antihyperglycemic drugs, both as monotherapy and in combination with other antihyperglycemic drugs and insulin; while the evidence base for its cardiovascular profile is only gaining momentum. Thus, the purpose of this review is to highlight the cardiovascular effects of metformin in the context of recent research.

show abstract

067 Metformin in insulin resistant LV dysfunction, a double-blind, placebo controlled trial (Tayside trial)

Cited by 2 publications

References 0 publications

Glucose and Insulin Abnormalities in Patients with Heart Failure

Glucose and Insulin Abnormalities in Patients with Heart Failure

Cardiovascular Effects of Metformin

Contact Info

Product

Resources

About